Search

Methylene blue dye, being toxic, carcinogenic and non-biodegradable, poses a serious threat for human health and environmental safety. The effective and time-saving removal of such industrial dye necessitates the use of innovative technologies such as silver nanoparticle-based catalysis. Utilizing a pulsed Nd:YAG laser operating at the second harmonic generation of 532 nm with 2.6 J energy per pulse and 10 ns pulse duration, Ag nanoparticles were synthesized via an eco-friendly method with sodium dodecyl sulphate (SDS) as a capping agent. Different exposure times (15, 30, and 45 min) resulted in varying nanoparticle sizes. Characterization was achieved through UV–Vis absorption spectroscopy, scanning electron microscopy (SEM) imaging, and energy dispersive X-ray (EDX). Lorentzian fitting was used to model nanoparticle size, aligning well with SEM results. Mie's theory was applied to evaluate the absorption, scattering, and extinction cross-sectional area spectra. EDX revealed increasing Ag and carbon content with exposure time. The SDS-caped AgNPs nanoparticles were tested as catalyst for methylene blue degradation, achieving up to 92.5% removal in just 12 min with a rate constant of 0.2626 min−1, suggesting efficient and time-saving catalyst compared to previously reported Ag-based nanocatalysts. [ABSTRACT FROM AUTHOR]

Background: Alcohol septal ablation (ASA) is recommended for moderate to severe symptomatic patients with hypertrophic obstructive cardiomyopathy. The current guidelines don not recommend particular alcohol doses and the amount of alcohol injected into the septal artery is based more on the interventionalist's decision rather than on systematic evidence. Our objective is to execute a comprehensive assessment of the efficacy and safety of low alcohol doses (1-2 ml)) in comparison to large ones (2-4 ml)., Methods: Multiple databases, encompassing PubMed, WOS, Scopus, Embase, and Cochrane library were systemically assessed from inception to October 2023. Randomized controlled trials (RCTs) and observational studies comparing low-alcohol and high-alcohol dose in patients with HOCM was included. The main outcome was creatine kinase-MB (CK-MB). The secondary ones are septal thickness, left ventricular outflow pressure gradient, and atrioventricular (AV) block., Results: Eight studies, with a total of 1446 individuals, were finally involved in our investigation. low alcohol doses showed lower CK-MB levels relative to high ones (MD=-0.93, 95% CI [-1.15 to -0.72], P = 0.00001). Furthermore, in terms of septal thickness, left ventricular outflow pressure gradient, and AV block, neither of the two doses was preferred., Conclusion: We propose that the low alcohol dose is equally effective as the high dose. moreover, the low alcohol dose was associated with a lower CK-MB levels in comparison to the high one., Prospero Registration: CRD42024511537., (© 2024. The Author(s).)

Background: Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF). However, the difference in the clinical effects between eplerenone and spironolactone in individuals with HF remains uncertain. We aimed to assess the impact of eplerenone compared to spironolactone on clinical outcomes within the HF population., Methods: An extensive search was executed in several databases (PubMed, Web of Science, Scopus, Cochrane Library). All relevant studies evaluating eplerenone compared to spironolactone in patients with HF were included. Dichotomous data were pooled as Hazard ratio (HR) or Risk ratio (RR) with a 95% confidence interval (CI). Our main outcome was all-cause mortality. Secondary outcomes included death from cardiovascular causes, treatment withdrawal, and gynecomastia., Results: Ten studies, comprising 21,930 HF individuals, were included in our investigation. Eplerenone showed a lower risk of all-cause mortality (HR = 0.78, 95%CI [0.64 to 0.94], P = 0.009) and cardiovascular mortality (HR = 0.54, 95%CI [0.39, 0.74], P = 0.0001) compared to spironolactone. Furthermore, eplerenone exhibited a reduced risk of treatment withdrawal (RR = 0.69, 95% CI [0.62, 0.78], P = 0.0001) and gynecomastia (RR = 0.07, 95% CI [0.02 to 0.31], P = 0.0001) than spironolactone., Conclusion: Eplerenone revealed lower all-cause and cardiovascular mortality events in comparison to spironolactone. Moreover, eplerenone was associated with lower gynecomastia and treatment withdrawal events compared to spironolactone. Further well-designed randomized controlled trials are still warranted better to identify the clinical differences between eplerenone and spironolactone., Trial Registration: Protocol registration: https://doi.org/10.17605/OSF.IO/VNMGK., (© 2024. The Author(s).)

Background: Pulsed-field ablation (PFA) has emerged as an innovative alternative to radiofrequency (RF) and cryoablation because it selectively targets myocardial tissue. Thus, we aim to estimate the efficacy and safety of PFA versus thermal ablation for atrial fibrillation (AF) ablation., Methods: A systematic review and meta-analysis were retrieved from PubMed, WOS, SCOPUS, EMBASE, and CENTRAL through September 2023. We used RevMan V. 5.4 to pool dichotomous data using risk ratio (RR) and continuous data using mean difference (MD) with a 95% confidence interval (CI). PROSPERO ID: CRD42023480321., Results: We included 17 studies with a total of 2255 patients. PFA was significantly associated with a decreased incidence of AF recurrence (RR: 0.66 with 95% CI [0.51, 0.87], p  = .003). However, there was no significant difference between PFA and thermal ablation in arrhythmia recurrence (RR: 0.92 with 95% CI [0.74, 1.46], p  = .42). PFA was significantly associated with decreased total procedure time (MD: -15.15 with 95% CI [-20.23, -10.07], p  < .00001), decreased heart rate change (MD: -7.39 with 95% CI [-12.16, -2.62], p  = .002), decreased phrenic nerve palsy (RR: 0.38 with 95% CI [0.15, 0.98], p  = .05), and reduced esophageal lesions (RR: 0.09 with 95% CI [0.01, 0.69], p  = .02). On the contrary, PFA was significantly associated with increased pericardial tamponade (RR: 6.14 with 95% CI [1.43, 26.33], p  = .01)., Conclusion: PFA was significantly associated with decreased AF recurrence, total procedure time, heart rate change, phrenic nerve palsy, esophageal lesion, and increased incidence of pericardial tamponade compared with thermal ablation., Competing Interests: Disclosures for Dr. Annabelle S. Volgman (October 2023) Consulting—Sanofi, Pfizer, Janssen; Clinical Trials: Janssen, Novartis and NIH Clinical Trials; Stock: Apple, Inc while the other authors declare no conflict of interest., (© 2024 The Author(s). Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society.)